as mentioned in i4u
New Simple, Inexpensive Therapy Shows Promise in Treating Depression
New Simple, Inexpensive Therapy Shows Promise in Treating Depression
A simple and inexpensive therapy has shown promise for treating depression and it could potentially replace cognitive behavioral therapy (CBT), a gold standard treatment, in future.CBT is the most widely recommended intervention for treating depression and other mental disorders but most of the patients who need therapy for depression are unable to receive this treatment as they cannot either afford it or had to endure long waits to make an appointment.Behavioral Activation (BA), on the other hand, is psychotherapy or talking therapy that requires minimal training and can be delivered by junior staff in place of a specialist, making it more accessible than CBT.
in the same way benzinga
Sangamo BioSciences Reveals New Gene Therapy Clinical Development Program For Hemophilia A Treatment - Sangamo BioSciences, Inc. (NASDAQ:SGMO)
Sangamo BioSciences Reveals New Gene Therapy Clinical Development Program For Hemophilia A Treatment - Sangamo BioSciences, Inc. (NASDAQ:SGMO)Sangamo BioSciences, Inc. (NASDAQ: SGMO) revealed the presentation of preclinical data supporting the clinical development of its new proprietary gene therapy for hemophilia-A treatment.The company stated that this fresh therapeutic consisted of an adeno-associated virus (AAV) cDNA human Factor 8 (hF8) construct fueled by its proprietary synthetic liver specific promoter.According to the company, in preclinical trials, it demonstrated a minimum of three times more potent than the current AAV-based cDNA constructs that is currently under evaluation for the treatment of hemophilia A.Sangamo BioSciences said the data would be presented at the World Federation of Hemophilia (WFH) 2016 World Congress that is being held in Orlando from July 24 – 28.
furthermore prnewswire
Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of
Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of
RICHMOND, Calif., July 26, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the presentation of preclinical data that supports the clinical development of its new proprietary gene therapy for the treatment of hemophilia A.This new therapeutic comprises an adeno-associated virus (AAV) cDNA human Factor 8 (hF8) construct driven by Sangamo's proprietary synthetic liver specific promoter, which in preclinical studies is at least three times more potent than existing AAV-based cDNA constructs currently under evaluation for the treatment of hemophilia A."We have compelling preclinical data from this AAV cDNA therapeutic which suggest its potential to be 'best in class' in this highly competitive field," said Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development.
No comments:
Post a Comment